Streptomyces microorganism useful for the preparation of (R)-baclofen from the racemic mixture
AssigneeNational Research Council of Canada
InventorsWayne Levadoux, Denis Groleau, Michael Trani, Robert Lortie
Life of this patent
Estimating the term…
Abstract
The invention disclosed relates to the biological production of substantially isomerically pure (R)-baclofen and structurally related compounds, from the racemic mixture of (R)- and (S)-isomers thereof, and to the isolation of a Streptomyces microorganism from Nature which is capable of preferentially metabolizing one of the isomers while showing minimal metabolic activity on the other isomer. A fermentation or bioconversion process using this microorganism or the cell-free enzymes derived therefrom for the biological resolution of a racemic mixture of (R)- and (S)-baclofen and structurally related compounds is also disclosed.
Claims15
A process for the production of a substantially isomerically pure isomer of a compound of structural formula II ##STR3## wherein R is NH.sub.2 or substituted NH.sub.2, R.sub.1 is phenyl or p-halo-substituted phenyl, R.sub.2 is H, lower-alkyl, NH.sub.2, Cl, or a metal salt thereof and C* is a chiral carbon, comprising contacting a racemic mixture of the (R)- and (S)-isomers of a compound of formula II, with a biologically purified microorganism, identified as Streptomyces halstedii strain no. 39, ATCC Deposit Accession No. 55794 or the cell-free enzymes derived therefrom, in a suitable aqueous culture medium, to selectively metabolize one of the isomers, while having minimal activity on the other isomer, and recovering the substantially isomerically pure unreacted isomer.
A biologically purified culture of a Streptomyces microorganism identified as Streptomyces halstedii strain no. 39, ATCC Deposit Accession No. 55794 and enzymes derived therefrom.
A biologically purified microorganism, identified as Streptomyces halstedii strain no 39, ATCC Deposit Accession No. 55794.
Dependencies are inferred from the claim text.